BC
SNDX icon

Bridgefront Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Bridgefront Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Sell
9,386
-21,715
-70% -$452K 0.05% 450
2026
Q1 		$727K Buy
31,101
+11,349
+57% +$247K 0.18% 190
2025
Q4 		$415K Sell
19,752
-2,096
-10% -$36.6K 0.1% 312
2025
Q3 		$336K Buy
+21,848
New +$286K 0.1% 358
2024
Q4 		– Sell
-20,346
Closed -$392K – 770
2024
Q3 		$392K Buy
+20,346
New +$420K 0.15% 254

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Bridgefront Capital's SNDX Position: Q2 2026 in Review

Bridgefront Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 70% in Q2 2026, selling an estimated $452K and leaving 9,386 shares worth $205K. The position accounts for 0.05% of the portfolio, ranked #450.

Bridgefront Capital first reported a position in SNDX in Q3 2024 and has held it in 5 quarters since. The position peaked at $727K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Bridgefront Capital held 9,386 shares of Syndax Pharmaceuticals worth $205K as of Q2 2026.
  • Bridgefront Capital sold 21,715 Syndax Pharmaceuticals shares in Q2 2026, an estimated $452K.
  • Syndax Pharmaceuticals made up 0.05% of Bridgefront Capital's portfolio in Q2 2026, its #450 holding.
  • Bridgefront Capital first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Bridgefront Capital's Syndax Pharmaceuticals position peaked at $727K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.